top of page
iPharmaCenter
ipharmacenter Consulting services
ipharmacenter
Consulting services
ipharmacenter
Consulting services
ipharmacenter
Consulting services
Home
Pharma
US FDA Approvals
North America
China Drug Approvals
Japan Drug Approvals | Healthcare
India Drug Approvals
APAC - Drug Approvals
LACAM
Europe
Canada Drug Healthcare News
Brazil - Drug approvals
EMA News
APAC
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
NICE Assessment Outcomes
G-BA Assessment Outcomes
APAC - Healthcare News
Lacam Healthcare News
Healthcare Policies
Conferences
All News
For sponsored articles, link insertions, and advertisements, please write to
info@ipharmacenter.com
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter
TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024 | BIGGEST PHARMA OF 2024 Sl No Company Q1 Q2 Q3 Total Best selling products 1 JOHNSON AND JOHNSON $21.8 $43.8 $66.1 $88.8 Stelara, Darzalex, Imbruvica 2 ROCHE $15.8 $34.8 $51.9 $66.4 Ocrevus, Perjeta, Tecentriq, Hemlibra, Kadcyla, Alecensa, Mabthera/Rituxan 3 PFIZER $14.9 $28.2 $45.9 $63 Comirnaty, Paxlovid, Prevenar 13, Ibrance, Eliquis 4 MERCK $14.0 $28.4 $43.4 $57 Keytruda, Lagevrio, Januvia, Gardasil/Gardasil9 5 ABBVIE $12.
ipharmaservices
Feb 2
FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter
The U.S. has granted approval for Enhertu as the first HER2-targeted treatment for patients with HER2-low or HER2-ultralow metastatic...
ipharmaservices
Jan 29
bottom of page